Seismic raises $121M to enter immunology space spotlighted by argenx, Immunovant and othersnews2023-12-04T12:00:08+00:00December 4th, 2023|Endpoints News|
AstraZeneca inks $247M deal with generative AI shop Absci to develop antibody drug for cancernews2023-12-04T11:50:55+00:00December 4th, 2023|Endpoints News|
FDA approves Lilly’s BTK inhibitor Jaypirca for two more blood cancersnews2023-12-04T10:24:53+00:00December 4th, 2023|Endpoints News|
Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger dealnews2023-12-04T09:40:43+00:00December 4th, 2023|Endpoints News|
FDA’s CAR-T safety probe; AbbVie’s $10B ADC wager; Pfizer’s GLP-1 setback; Acelyrin’s CRO drama; and morenews2023-12-02T11:00:26+00:00December 2nd, 2023|Endpoints News|
Samsung Bioepis strikes deal for Stelara biosimilar, but launch likely won’t come in time for an IRA exemptionnews2023-12-01T20:43:21+00:00December 1st, 2023|Endpoints News|
Apellis’ eye disease drug gets safety label update for rare inflammation side effectnews2023-12-01T19:22:24+00:00December 1st, 2023|Endpoints News|
Pfizer, Idorsia and AbbVie drug brands lead the way in pharma digital marketing — studynews2023-12-01T19:03:25+00:00December 1st, 2023|Endpoints News|
EMA sends more questions to GLP-1 makers over possible risk of suicide, self-harmnews2023-12-01T18:47:14+00:00December 1st, 2023|Endpoints News|
Novartis taps ‘Sopranos’ actress for new multiple sclerosis Kesimpta campaignnews2023-12-01T17:49:12+00:00December 1st, 2023|Endpoints News|
